Hematologic Oncology

Drs Cutler and Safah look to the future of chronic GvHD treatment and discuss ongoing research, highlighting studies investigating axatilimab and abatacept.

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss luspatercept with or without ruxolitinib for the treatment of anemia in patients with myelofibrosis. The combination has demonstrated promise in reducing transfusion dependency, as seen in data from ACE-536-MF-001, with ongoing phase 3 trials.

Andrew Kuykendall, MD, highlights the potential of selinexor plus ruxolitinib in JAK inhibitor-naïve patients with MF based on promising response rates in XPORT-MF-034 updated results, with plans for a phase 3 study. He also noted the need to manage nausea as a adverse effect.

A hematologist-oncologist discusses a recent abstract looking at subcutaneous mosunetuzumab in the first line for patients with follicular lymphoma.

Lori A. Leslie, MD, a specialist in lymphoma, provides an overview of recent changes in the overall treatment landscape.

The FDA has granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for the treatment of adult patients with newly diagnosed, Philadelphia chromosome–positive acute lymphoblastic leukemia.

Experts on myelodysplastic syndromes offer their key takeaways from the 2023 ASH Annual Meeting in the higher-risk disease space.

Hematologist-oncologists review clinical trial data updates presented at ASH 2023 in higher-risk MDS.

In case you missed it, read a recap of every episode of OncLive On Air recorded in February 2024.

The FDA has accepted the resubmission of the BLA seeking the approval of denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma.

A case study of a patient with pre-B cell acute lymphoblastic leukemia showed helical tomotherapy with IMRT-based TBI is a viable option for organ sparing.

The FDA has granted orphan drug designation to LYT-200 for the treatment of acute myeloid leukemia.

Drs Safah and Cutler discuss treatment practices for patients with steroid-refractory graft-vs-host disease and highlight patients who are steroid dependent.

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

Raajit K. Rampal, MD, PhD, discusses promising data on navtemadlin plus ruxolitinib for patients with myelofibrosis who had suboptimal responses to ruxolitinib, showing significant improvements in spleen and symptom responses, with further phase 3 studies anticipated.

Andrew Kuykendall, MD, reviews data from TRANSFORM-1 on navitoclax plus ruxolitinib for untreated myelofibrosis, highlighting consistent response rates, no significant symptom improvement with the combination, and challenges managing thrombocytopenia caused by navitoclax, despite its activity and potential as a second-line treatment option.

Dr McCloskey highlights challenges in adverse event management and discusses unmet needs in the treatment of patients with leukemia.

James K. McCloskey, MD, provides an overview of key takeaways from recent studies presented at the 2023 ASH Annual Meeting in leukemia.

Comprehensive insights on the current treatment landscape and remaining unmet needs for patients with higher-risk MDS.

The panel discusses emerging clinical trials in the MDS treatment space and offers key takeaways from the 2023 ASH Annual Meeting.

TERN-701 has received orphan drug designation from the FDA for the treatment of patients with chronic myeloid leukemia.

Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.

Andrea Porpiglia, MD, MSc, FACS, and Sanjay Reddy, MD, FACS describe what makes the Complex General Surgical Oncology Fellowship at Fox Chase unique.

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies